Equaly

Equaly is a technology-based start-up biotech. What we aim at, through our technology solutions, is partnering with product-based biotech companies to help to contribute to their portfolio strategy, developing or improving their drugs, and thereby contribute to their market expansion and the offer of better patient treatments in the field of immunology. Equaly’s research is sustained by robust expertise and patents, financed by public, seed, or early-growth private financing. These assets are made accessible through various models of collaboration: https://equaly.be/partnering/